Andy Behrens, Pete Thamel, Krysten Peek and Preston Johnson break down the West Region of the 2021 NCAA men’s tournament field - including number one overall seed Gonzaga.
Andy Behrens, Pete Thamel, Krysten Peek and Preston Johnson break down the West Region of the 2021 NCAA men’s tournament field - including number one overall seed Gonzaga.
Now that the Royal Family has said farewell to Prince Philip, attention will turn to Queen Elizabeth II’s 95th birthday on Wednesday and, in coming months, the celebrations marking her 70 years on the throne. Then in 2017, he represented the queen at the annual Remembrance Day ceremony marking the end of World War I, laying the monarch’s wreath at the foot of the Cenotaph in London.
The European Union is seeking to encourage greater investment from Taiwan especially its semiconductor firms, the bloc's top diplomat in Taipei said on Tuesday, amid a global chip shortage that has impacted auto makers like Volkswagen. Tech powerhouse Taiwan, home to companies like Taiwan Semiconductor Manufacturing Co Ltd (TSMC), has become front and centre of efforts to resolve that shortfall, whose impact is now being felt in consumer electronics too. German Economy Minister Peter Altmaier wrote to Taiwan's government this year asking for help to ease tight chip supplies, and Europe is also encouraging more chip production at home.
The ‘Big Six’ clubs will be excluded from an emergency Premier League meeting on Tuesday to discuss a response to the proposals.
The retailer says the number of people in its stores in England and Wales is back to pre-pandemic levels.
Xu frequently uses the lion in his work to exemplify his faith in the rise of the Chinese nation.
In the past 30 days, more than 25,000 people tested positive compared to just 7,501 in January, among a population of 2.75 million, although there is no evidence linking sporting events to the surge.
Internationally respected corporate executive brings over 30 years of leadership in life sciences to BiotalysGhent, BELGIUM, April 20, 2021 (GLOBE NEWSWIRE) -- Biotalys Appoints Simon Moroney as Chairman of the Board Internationally respected corporate executive brings over 30 years of leadership in life sciences to Biotalys Ghent, BELGIUM – 20 April 2021 – Biotalys, an AgTech company focused on addressing food protection challenges to enable a more sustainable and safer food supply, is pleased to announce the appointment of Simon Moroney as Chairman of the Board, following the Company’s Annual General Meeting end of last week. Simon brings over 30 years of industry leadership and research experience to the Biotalys Board. From 1992 to 2019, he was co-founder and CEO of MorphoSys, a leading biotechnology company focused on the treatment of cancer and autoimmune diseases. At MorphoSys, Simon played a central role in establishing the company as a driving force in the field of therapeutic antibodies and led the company to a $239m initial public offering on the Nasdaq stock exchange in 2018. He currently sits on the board of Novartis as a non-executive Director. Simon has been recognized and awarded with the German Cross of the Order of Merit for his work and contribution to the biotechnology industry. “Simon is an eminent figure in the global life sciences community, and his appointment as Chairman of the Board demonstrates our ambition to establish Biotalys at the forefront of innovation in agricultural technology. Simon’s extensive experience and proven track record will be invaluable to our team as we continue to develop our pipeline of antibody-derived biocontrol solutions. On behalf of Biotalys and the Board of Directors, I warmly welcome Simon and look forward to drawing upon his strategic and operational judgment,” said Patrice Sellès, CEO of Biotalys. “I would also like to deeply thank Lieven De Smedt for his professional contribution as a consensus-building Chairman over the past six years and, in particular, for his active role in the capital rounds and his mentorship in building the company’s management team.” “I strongly believe that Biotalys has great potential to become an important force of innovation in the global AgTech sector, addressing the urgent need for more sustainable food production and offering effective alternatives to conventional crop protection products that are safer for the environment, grower and consumer,” added Simon Moroney, newly appointed Chairman of the Board at Biotalys. “I am excited to join as Chairman, where I believe my experience in both antibody technology and in building innovative companies from early stage through to commercialization leaves me well placed to guide the Company at this key phase in its development. I look forward to working closely with Patrice and the Biotalys leadership team as we continue to build and develop our pipeline of transformative biocontrol solutions.” Simon holds a D. Phil in Chemistry from the University of Oxford and has held positions in the Department of Pharmacology at the University of Cambridge, as Assistant Professor in the Chemistry Department, University of British Columbia and as Associate and Lecturer in the Chemistry Department of the ETH Zurich. Today’s announcement follows the recent submissions to the EU and US regulatory authorities of the registration dossier for the Company’s first protein-based biocontrol product, Evoca™ *, Biotalys’ first biofungicide which aims to provide fruit and vegetable growers with a novel mode of action to control key pathogens in selected crops. * Evoca™: Pending Registration. This product is not currently registered for sale or use in the European Union, the United States or elsewhere and is not being offered for sale. About Biotalys Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective products with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and has raised €62.8 million (US$74,9 million) to date from Belgian and international specialised investors. The Company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com. For further information, please contact Toon Musschoot, Strategic Communications ManagerT: +32 (0)9 274 54 00E: Toon.Musschoot@biotalys.com Consilium Strategic CommunicationsAmber Fennell, Chris Gardner, Chris WelshT: +44 (0)203 709 5700E: Biotalys@consilium-comms.com
Geico has filed a data breach notice with the California attorney general’s office, admitting that fraudsters had stolen customers' driver's license numbers from its website.
Singer reshared photo on social media
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 19, 2021. Due to the situation resulting from the Corona virus, the Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. ENTITLEMENT TO PARTICIPATE AND NOTICE Shareholders who wish to participate in the Meeting must (i) be recorded in the register of shareholders maintained by Euroclear Sweden AB on Monday, May 10, 2021, and (ii) notify the Company of their intention to attend the Meeting no later than Tuesday, May 18, 2021 by casting its advance vote in accordance with the instructions under the heading “Advance voting” below so that the advance voting form is received by the Company no later than that day. In order to be entitled to participate in the meeting, shareholders whose shares are registered in the name of a nominee must, in addition to announcing their intention to participate in the meeting, request that their shares be registered in their own name so that the shareholder is recorded in the register of shareholders as of 10 May 2021. Such registration may be temporary (so-called voting rights registration) and request for such registration shall be made to the nominee in accordance with the nominee’s routines at such time in advance as prescribed by the nominee. Voting rights registrations that have been made no later than the second banking day after 10 May 2021 will be taken into account when preparing the share register. There are 217,971,720 shares and votes in Active Biotech. The Company holds no treasury shares. ADVANCE VOTING The shareholders may exercise their voting rights at the Meeting by voting in advance, so called postal voting in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of shareholders’ meetings in companies and other associations. A special form shall be used for advance voting. The form is available on the Company’s website www.activebiotech.com. The advance voting form is considered as the notification of attendance to the Meeting. The completed voting form must be submitted to the Company no later than Tuesday, May 18, 2021. The completed form shall be sent to Active Biotech AB (publ), Attn: Susanne Jönsson, Scheelevägen 22, SE-223 63 Lund, Sweden (mark the envelope “Annual General Meeting”). A completed form may also be submitted electronically to email@example.com. If the shareholder votes in advance by proxy, a power of attorney shall be enclosed to the form. Proxy forms are provided at the Company’s website, www.activebiotech.com, and sent to shareholders that so request. If the shareholder is a legal entity, a certified copy of a registration certificate or corresponding document indicating the authorized signatories of the legal entity shall be enclosed to the form. The shareholder may not qualify the advance vote with special instructions or conditions. If so, the vote is invalid in its entirety. Further instructions and conditions is included in the form for advance voting. PROPOSED AGENDA 1. Election of Chairman of the Meeting 2. Election of one or two persons to verify the minutes 3. Preparation and approval of the voting list 4. Approval of the agenda for the Meeting 5. Determination of whether the Meeting has been duly convened 6. Presentation of the Annual Report and the Auditors’ Report, and the Consolidated Accounts and the Auditors’ Report for the Group7. Resolution concerning the adoption of the Income Statement and the Balance Sheet, and the Consolidated Income Statement and the Consolidated Balance Sheet8. Resolution concerning the disposition of the Company’s results pursuant to the adopted Balance Sheet9. Resolution on discharge from liability of the members of the Board of Directors and the CEO 10. Determination of the number of members and alternate members of the Board of Directors and the number of auditors and alternate auditors 11. Determination of fees payable to the Board of Directors and auditor12. Election of the Board of Directors, Chairman of the Board and auditor a) re-election of Michael Shalmi b) re-election of Uli Hacksell c) re-election of Peter Thelin d) re-election of Axel Glasmacher e) re-election of Aleksandar Danilovski f) re-election of Elaine Sullivan g) re-election of Michael Shalmi as chairman of the board h) re-election of KPMG AB as auditor 13. Presentation of the Board of Directors’ remuneration report for approval 14. Resolution concerning Election Committee 15. The Board of Director’s proposal regarding share issue authorization PROPOSED RESOLUTIONS Persons to approve the minutes (item 2) Magnus Svensson and Werner Burghard, or if one or both of them have an impediment to attend, the person or persons instead appointed by the Board of Directors, are proposed to be elected to approve the minutes. The task of approving the minutes also includes verifying the voting list and that the advance votes received are correctly stated in the minutes of the Meeting. Voting list (item 3) The voting list proposed for approval under item 3 on the agenda is the voting list prepared by the company, based on the shareholders’ register and advance votes received, and verified by the persons elected to verify the minutes. Disposition of the Company’s results (item 8) The Board of Directors proposes that no dividend is paid and that the Company’s accumulated loss shall be carried forward. Board of Directors, etc. (items 1 and 10 – 12) The Election Committee, comprising Michael Shalmi (Chairman of the Board), Mats Arnhög (MGA Holding), Per Colleen (Fourth Swedish National Pension Fund) and Peter Thelin proposes the following: Chairman of the Meeting: attorney-at-law Erik Sjöman or, if he has an impediment to attend, the person instead appointed by the Board of Directors. Number of members and alternate members of the Board of Directors: six ordinary members with no alternates. Fees payable to the Board of Directors: unchanged SEK 500,000 to the Chairman of the Board and SEK 200,000 to each of the other Board members who are not employed by the Company. A member of the Board who performs work for the Company outside the scope of the Board work may also receive remuneration on market terms for such work performed. Board of Directors: re-election of Michael Shalmi, Uli Hacksell, Peter Thelin, Axel Glasmacher, Aleksandar Danilovski and Elaine Sullivan. Chairman of the Board: re-election of Michael Shalmi. Number of auditors and alternate auditors: one auditor with no alternates. Fees payable to the auditor: in accordance with approved invoices within the scope of the tender. Auditors: re-election of KPMG AB. The proposal regarding auditor is in accordance with the recommendation by the Audit Committee. For further information on the board members proposed for re-election, reference is made to the Company’s website, www.activebiotech.com. Election Committee (item 14) The Election Committee proposes that the Meeting assigns the Chairman of the Board the task of convening an Election Committee, based on the ownership structure at the end of September 2021, comprising the Chairman of the Board and one member appointed by each of the three largest shareholders of the Company. The Election Committee shall remain in place until the following Election Committee has been appointed. If a member of the Election Committee no longer represents one of the three largest shareholders in the Company, the Election Committee is entitled to dismiss the member. In the event that a member of the Election Committee resigns or is dismissed, the Election Committee may appoint another member nominated by the major shareholders to replace such a member. The Election Committee shall perform its duties in accordance with the stipulations for Election Committees stated in the Swedish Code of Corporate Governance. Share issue authorization (item 15) The Board proposes that the Annual General Meeting resolves to grant authorization to the Board, for a period that does not extend past the date of the next Annual General Meeting, on one or several occasions, with or without pre-emptive rights for the shareholders, to resolve on the issue of new shares and/or convertibles entitling to conversion to shares. It shall also be possible to make such an issue resolution stipulating in-kind payment, the right to offset debt or other conditions. The number of shares issued, or which may arise through the conversion of convertibles issued with the support of the authorization, may correspond to not more than 30 percent of the total number of shares in the Company after utilization of the authorization. The purpose of the authorization is to enable the financing, commercialization and development of the Company’s projects and to provide flexibility in commercial negotiations relating to partnerships. QUESTIONS AND SHAREHOLDERS’ RIGHT TO REQUIRE INFORMATION If any shareholder should so request and the Board assesses that this can be done without significant damage to the Company, the Board of Directors and the CEO of the Company shall provide information about conditions that could affect the assessment of items on the agenda, the Company’s and subsidiaries’ financial position as well as the Company’s relationship to other group companies. A request for such information shall be made by e-mail to firstname.lastname@example.org or by regular post to Active Biotech AB (publ), Attn: Susanne Jönsson, Scheelevägen 22, 223 63 Lund, Sweden no later than ten days prior to the Meeting, that is Sunday, May 9, 2021. The information is provided by being made available at the Company’s offices and the Company’s website, www.activebiotech.com, no later than Friday, May 14, 2021. Furthermore, the information will be sent within the same time period to the shareholder who so request and provide its postal address. DOCUMENTATION, ETC. The Annual Report, the Board of Directors’ remuneration report and other supporting resolution documentation will be presented by being held available at the Company’s premises at Scheelevägen 22 in Lund, Sweden, and on the Company’s website, www.activebiotech.com, not later than three weeks prior to the Meeting. The documents will be sent to shareholders who request a copy and specify their postal address. The register of shareholders for the Meeting is also made available at the Company’s premises. Processing of personal data For information about the processing of your personal data, please refer to https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Active Biotech’s AB (publ) corporate registration number is 556223-9227 and its registered office is in Lund, Sweden. Lund, Sweden, April 2021 The Board of Directors of Active Biotech AB (publ) Attachment 210420_Notice Annual General Meeting
Amsterdam/’s-Hertogenbosch, the Netherlands, 20 April 2021 In the period from 13 April 2021 until 19 April 2021 Van Lanschot Kempen has repurchased 46,885 of its own shares (depositary receipts for Class A ordinary shares). The shares were repurchased at an average price of €24.45 per share for a total amount of €1,146,315. These repurchases are part of the share buy-back programme for at most 400,000 of own shares, which was announced on 25 February 2021. The total number of shares repurchased to date is 274,607. More information, including a detailed overview of the repurchase transactions under this programme, is available on www.vanlanschotkempen.com/sharebuyback. Media Relations: +31 20 354 45 85; email@example.comInvestor Relations: +31 20 354 45 90; firstname.lastname@example.org About Van Lanschot Kempen Van Lanschot Kempen, a wealth manager operating under the Van Lanschot, Kempen and Evi brand names, is active in Private Banking, Asset Management and Merchant Banking, with the aim of preserving and creating wealth, in a sustainable way, for both its clients and the society of which it is part. Van Lanschot Kempen, listed at Euronext Amsterdam, is the Netherlands’ oldest independent financial services company with a history dating back to 1737. For more information, please visit vanlanschotkempen.com Disclaimer This press release does not constitute an offer or solicitation for the sale, purchase or acquisition in any other way or subscription to any financial instrument and is not a recommendation to perform or refrain from performing any action. This press release is a translation of the Dutch language original and is provided as a courtesy only. In the event of any disparities, the Dutch language version will prevail. No rights can be derived from any translation thereof. Attachment 210420 Share buy-back programme weekly press release
This victory on Monday helped CSK to jump from 4th position to 2nd position in the points table.
Hosts look to maintain momentum after their FA Cup semi-final win at the weekend
Everything you need to know ahead of the top-flight clash
All there is to know before the top-flight meeting
All the important info around the top-flight game
London's Francis Crick Institute was already a magnet for investors in the capital's so-called Knowledge Quarter, but the coronavirus pandemic has lifted interest in offices and laboratories dedicated to life sciences to a new level. Investors have been drawn into European real estate dedicated to life sciences, which spans sectors such as biomedical devices and pharmaceuticals, by an ageing population and strong academic research in the region. "Life sciences have never been more under the spotlight because of what we've all had to endure," Peter Ferrari, chief executive of real estate investor AshbyCapital, told Reuters.
SP Group A/S has set new sales record for a quarter. All our 28 productions plants around the world are up running and our six sales and service companies are working. We still do all we can to protect each other, our partners and our relatives during the Corona pandemic. Revenue was up by DKK 51.7 million to DKK 598.1 million in Q1 2021, or by 9.5 % relative to the year-earlier period. Operating income (EBITDA) for Q1 2021 was DKK 105.2 million, against DKK 87.9 million in Q1 2020 equal to a EBITDA margin of 17.6 %. Earnings before interest and tax (EBIT) came to DKK 68.8 million in Q1 2021, against DKK 53.8 million in Q1 2020. Profit before tax was DKK 67.5 million in Q1 2021, against DKK 50.2 million in Q1 2020 equal to a EBT margin of 11.3 %. There was a positive cash inflow from operating activities of DKK 66.3 million in Q1 2021, against DKK 79.6 million in Q1 2020. Net interest-bearing debt (NIBD) amounted to DKK 702.4 million at 31 March 2021, against DKK 853.3 million at 31 March 2020. At 31 December 2020, NIBD was DKK 686.1 million. NIBD was 1.9 times LTM EBITDA. Due to the spread of the Corona virus and the actions taken by authorities, our level of activities and cash flows in the coming months are still subject to great uncertainty.Due to the very positive development in Q1 with high growth and good product mix, the outlook for FY 2021 has been changed:We are now expecting a growth in revenue of 4-12 % (previously 3-10 %)A EBITDA margin of 16-18 % (previously 16-17 %)A EBT margin of 9-12 % (previously 9-10 %). Statement by CEO Frank Gad: “Despite the Corona pandemic, global turbulence, uncertain market prospects and volatile prices of raw materials, we have increased our sales and EBITDA again in Q1. The first quarter of 2021 marks our best quarter ever in terms of both top and EBITDA lines.” Our interim report for Q1 2021 will be released on 26 May 2021 - as previously announced. Attachment Meddelelse nr. 28 - Trading Update - ENG - 20 04 21
Republican Thomas Massie was the lone member to vote against the resolution
ViSi Mobile, used for non-invasive continuous vital signs monitoring, to identify early patient deterioration and prevent alarm fatigue is enhanced to now utilize advanced machine learning.San Diego, United States, April 20, 2021 (GLOBE NEWSWIRE) -- Sotera Wireless, a medical technology company in San Diego, California, has released its sixth (6th) version of software for the ViSI Mobile Vital Signs Monitoring System. The new version of software (Version 6.0.1) focuses on improving clinical workflow and patient recovery time in the general care / post-surgical areas of the hospital. The ViSi Mobile Vital Signs Monitoring System provides accurate, continuous, and non-invasive vital signs monitoring for patients in care units that are designed for patient recovery and the prevention of physiological deterioration. More details can be found at http://www.soterawireless.com The newly released software (6.0.1) utilizes advanced machine learning and delivers increased efficiencies to the clinical staff as they treat patients. The discrete measurement of specific cardiac variables allows “smart technology” to reduce alarm fatigue and improve QRS output. (The QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram. It is usually the central and most visually obvious part of the tracing; in other words, it’s the main spike seen on an ECG line.) By incorporating advancements that provide increased insight into cardiac and vascular profiles, cardiac data output is improved and physiological changes to the patient’s circulatory system are detected immediately. Early detection of changes in a continuous non-invasive blood pressure measurement are key factors in recognizing early physiological deterioration. This new version of software contains enhanced detection algorithms that allow machine learning to monitor the blood pressure profile and brings enhanced efficiencies to the patient setup and parameter limits. ViSi Mobile improves the automated vital signs collection process; seamlessly transcribing data into a patient’s electronic medical records by utilizing more efficient coding algorithms. Relieving the administrative burden of active charting allows clinical teams to focus on treatment plans, the patient’s recovery, and the “patient experience” while in the recovery unit. Poor signal quality in some hospital units slows the patient set-up of continuous vital sign monitors. Using advanced machine learning algorithms to improve data classification, the latest ViSi Mobile software reduces setup time and shortens calibration of its novel, continuous non-invasive blood pressure measurement. Up to 75% of adverse events and preventable deaths occur outside the ICU. Vital sign collection typically is ordered according to unit policy and not according to patient need. Dangerous patient deterioration can occur in the interim between a physical vital sign spot check: which can be as long as four (4) to six (6) hours. ViSi Mobile addresses this “gap” in coverage with continuous non-invasive monitoring. Dr. Devin McCombie, CEO of Sotera Wireless said, “Our goal is to help hospitals improve patient safety and clinical workflow. Our newest software release allows ViSi Mobile to do these things even better by utilizing our database of more than 20 million hours of patient data to more accurately help the clinical staff recognize potential concerns.” Interested parties in the US can find more information by visiting http://www.soterawireless.com * AHA database, 2013 2 I2_Presentation_Diagnostics_Haraden.pdf CONTACT: Name: Matt Bacino Organization: Sotera Wireless, Inc. Address: 10020 Huennekens St, San Diego, CA 92121, United States Phone: +1-858-373-4824